Not everyone should be on a GLP-1, and a good provider screens people out as readily as in. This guide walks through who qualifies, who shouldn't take these medications at all, what gets weighed case by case, and the questions we'd have you ask yourself before you book.
The quick self-check
| Likely a good fit | Worth talking through | Not a candidate |
|---|---|---|
| BMI of 30 or higher, or 27 or higher with a weight-related condition like high blood pressure, prediabetes, high cholesterol, or sleep apnea | Diabetes medications, digestive conditions, gallbladder history, kidney issues, an upcoming surgery, oral birth control, or a history of disordered eating | Pregnant, breastfeeding, or trying to conceive; personal or family history of medullary thyroid cancer or MEN2; history of pancreatitis |
Who qualifies for weight loss injections?
The standard medical criteria for GLP-1 weight-loss medications are a BMI of 30 or more, or a BMI of 27 or more with at least one weight-related health condition. Those are the same thresholds used in the clinical trials and on the FDA labels for the approved weight-loss versions.
If you're looking to lose a stubborn ten pounds before an event, these medications are the wrong tool, and we'll tell you that at the consult. That's not us being stingy. The side effects, the cost, and the commitment only make sense when the medical benefit is real.
Who should not take GLP-1 medications
These are hard stops, not things we try to work around:
- Pregnancy, breastfeeding, or trying to conceive. Semaglutide should be stopped at least two months before a planned pregnancy.
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2). This is the boxed warning on Semaglutide and Tirzepatide, based on thyroid tumors seen in rodent studies.
- A history of pancreatitis.
- A known allergy to the medication or its ingredients.
Things we weigh case by case
None of these is an automatic no, but each one changes the conversation:
Diabetes medications. Taken with insulin or certain other diabetes drugs, GLP-1s can push blood sugar too low. That has to be coordinated with whoever manages your diabetes.
Digestive conditions. These medications slow how quickly your stomach empties. If you already have significant stomach-emptying problems or severe reflux, that matters.
Gallbladder and kidney history. Rapid weight loss can raise gallstone risk, and dehydration from vomiting or diarrhea can stress the kidneys.
Upcoming surgery or sedation. A slower-emptying stomach matters for anesthesia. Tell your surgeon and your anesthesiologist you're on a GLP-1.
Oral birth control. Tirzepatide can make birth control pills less effective, especially when you start and after each dose increase. A backup or non-oral method is recommended during those windows.
A history of disordered eating. An appetite-quieting medication can be helpful or harmful depending on that history. We'd want to talk about it openly, and sometimes the right answer is to work with a specialist first.
Five honest questions to ask yourself
1. Does my starting point fit the criteria?
Check your BMI against the thresholds above. If you're close to the line, bring your numbers and any relevant conditions to the consult and we'll go through it together.
2. Have I given the fundamentals a real try?
A real, steady effort counts, even an imperfect one. These medications work best for people whose biology keeps fighting their efforts, not as a first resort before any effort. Your history also helps us set realistic expectations.
3. Is anything on the rule-out list?
If anything in the hard-stop list applies to you, this isn't the right path right now. If something in the case-by-case list applies, bring it up at the consult, along with a list of your current medications.
4. Can I commit to the structure?
A weekly self-injection, a monthly check-in, and real attention to protein and movement so the weight you lose is mostly fat, not muscle. The medication without the structure tends to produce weaker results and more regain.
5. Are my expectations calibrated?
In the large clinical trials, people lost an average of about 15% of their body weight on Semaglutide and about 21% at the highest dose of Tirzepatide over roughly a year and a half. Averages hide a wide range: some people lose more, some much less. Results build over months, plateaus are normal, and in the Semaglutide trials people regained about two-thirds of the lost weight, on average, within a year of stopping. Going in knowing that is how people stick with it.
What about Retatrutide?
Retatrutide has shown strong results in clinical trials, but it is not FDA-approved. It's still being studied, and there's less long-term safety data than for Semaglutide or Tirzepatide. It's usually considered only after the other two, and only with closer monitoring. We'll walk you through exactly where the evidence stands if you ask about it.
What to bring to your consult
- A list of every medication and supplement you take, with doses.
- Any recent labs, especially A1C, thyroid, kidney, or liver results, if you have them.
- Your health history, including any thyroid, pancreas, gallbladder, or digestive issues, and your family's thyroid cancer history.
- What you've tried before for weight, and what got in the way.
- Your plans for pregnancy, if that's on the horizon at all.
None of it needs to be perfect. It makes the conversation more useful and helps us give you a straight answer faster.
What happens at the free consult
We go over your health history, current medications, goals, and anything from the lists above. If you're a good candidate, we talk through which medication makes sense to start with and what it will cost at your starting dose. If you're not, we tell you why, and if there's a better next step, like seeing your primary care provider, we'll say so.
If you're not a candidate right now
That's not a dead end. Depending on why, the next step might be working with your primary care provider on a condition that needs attention first, revisiting the question after a pregnancy, or focusing on strength training, protein, and sleep for a few months and seeing where that takes you. Sometimes the most useful thing a consult can do is save you from spending money on the wrong tool.
If you answered those five questions and you’re still interested, the free screening consult is for you. You can also read how weight loss injections work or see what they cost.
Frequently asked questions
What BMI do you need to qualify for Semaglutide?
The standard criteria are a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, prediabetes, high cholesterol, or sleep apnea. Final eligibility is confirmed at a consult.
Can I get weight loss injections to lose 10 or 15 pounds?
Usually not. If you don't meet the BMI criteria, the side effects, cost, and commitment generally outweigh the benefit, and we'll tell you so.
Who should not take Semaglutide or Tirzepatide?
Anyone who is pregnant, breastfeeding, or trying to conceive; anyone with a personal or family history of medullary thyroid carcinoma or MEN2; and anyone with a history of pancreatitis. Diabetes medications, digestive conditions, and upcoming surgery are reviewed case by case.
Can I take a GLP-1 if I'm planning a pregnancy?
No. These medications aren't used during pregnancy, and Semaglutide should be stopped at least two months before a planned pregnancy. Tell us about any pregnancy plans at your consult.
Do weight loss injections affect birth control?
Tirzepatide can reduce the effectiveness of birth control pills, especially at the start and after each dose increase. A backup or non-oral method is recommended during those periods.
Is Retatrutide FDA-approved?
No. Retatrutide is not FDA-approved and is still being studied in clinical trials. Results so far are promising, but there's less long-term safety data, so it's typically considered only after Semaglutide and Tirzepatide and with closer monitoring.
Sources
These are the main sources behind the numbers and safety information in this guide.
- Wegovy (semaglutide) prescribing informationU.S. National Library of Medicine, DailyMed. The FDA label: who it’s approved for, the boxed warning, side effects, and pregnancy guidance.
- Zepbound (tirzepatide) prescribing informationU.S. National Library of Medicine, DailyMed. The FDA label: who it’s approved for, the boxed warning, side effects, and the birth control interaction.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)Wilding JPH et al., New England Journal of Medicine, 2021. The large Semaglutide trial behind the “about 15%” average.
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)Jastreboff AM et al., New England Journal of Medicine, 2022. The Tirzepatide trial behind the “about 21% at the highest dose” average.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extensionWilding JPH et al., Diabetes, Obesity and Metabolism, 2022. Where the “regained about two-thirds within a year of stopping” finding comes from.
- Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative periodKindel TL et al., Clinical Gastroenterology and Hepatology, 2024. Why your surgeon and anesthesiologist need to know you’re on a GLP-1.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food and Drug Administration. On compounded versions, and why Retatrutide isn’t FDA-approved yet.